Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers (Q35043101)

6 August 2017

1 reference

title

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers (English)

1 reference

6 August 2017

1 reference

2

David L Bartlett

1 reference

6 August 2017

1

Herbert J Zeh

1 reference

6 August 2017

publication date

1 December 2002

1 reference

6 August 2017

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

12

1 reference

6 August 2017

page(s)

1001-1012

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700549

6 August 2017

exact match

0 references

cites work

A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

The complete DNA sequence of vaccinia virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Modulation of chemokines by poxvirus infections

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Vaccinia virus encodes a family of genes with homology to serine proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase 2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Regulation of angiogenesis by hypoxic stress: from solid tumours to the ovarian follicle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Deletion of the vaccinia virus growth factor gene reduces virus virulence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Vaccinia virus serpin-1 deletion mutant exhibits a host range defect characterized by low levels of intermediate and late mRNAs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Vaccinia virus host range genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Apoptosis and host restriction of vaccinia virus in RK13 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Complementation of a vaccinia virus host-range K1L gene deletion by the nonhomologous CP77 gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

CD40 ligand has potent antiviral activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Human gene marker/therapy clinical protocols

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700549

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700549

1 reference

6 August 2017

1 reference